Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
Sign Up to like & getrecommendations! Published in 2020 at "Antibiotics"
DOI: 10.3390/antibiotics9090539
Abstract: Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality. Echinocandins are utilized as the first-line treatment.… read more here.
Keywords: triterpenoid antifungal; auris infections; treatment; candida ... See more keywords